Abstract
Recently, the combining of different drugs has greatly improved response and survival rates in gynecological malignancies. Results are however far from being satisfactory. Treatments used in case of advanced or recurrent disease offer limited results in terms of long-term responses. The urgent need for new and more effective treatments has prompted researchers to investigate and propose new therapeutic strategies. One of the most interesting approaches that are being explored is constituted by immunotherapy. Currently, immunotherapeutic strategies include vaccination with peptide, viral vectors, carbohydrates and antiidiotypic antibodies. In addition, cell based immunotherapy has been adopted in vitro activated lymphocytes and dendritic cells. Most experience has been acquired in ovarian cancer and cervical cancer. Little has been investigated in endometrial and rare gynecologic neoplasms.
The clinical experiences and results achieved with immunotherapy in this setting of patients have been reviewed and the future avenues that are currently being explored have also been discussed.
Keywords: Anti-idiotypic antibody, cancer vaccine, cervical cancer, dendritic cells, gynecological cancer, immunotherapy, lymphocytes, ovarian cancer
Current Molecular Medicine
Title:Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Volume: 13 Issue: 4
Author(s): F. Bellati, C. Napoletano, I. Ruscito, V. Visconti, M. Antonilli, M.L. Gasparri, I.G. Zizzari, H. Rahimi, I. Palaia, A. Rughetti, P. Benedetti Panici and M. Nuti
Affiliation:
Keywords: Anti-idiotypic antibody, cancer vaccine, cervical cancer, dendritic cells, gynecological cancer, immunotherapy, lymphocytes, ovarian cancer
Abstract: Recently, the combining of different drugs has greatly improved response and survival rates in gynecological malignancies. Results are however far from being satisfactory. Treatments used in case of advanced or recurrent disease offer limited results in terms of long-term responses. The urgent need for new and more effective treatments has prompted researchers to investigate and propose new therapeutic strategies. One of the most interesting approaches that are being explored is constituted by immunotherapy. Currently, immunotherapeutic strategies include vaccination with peptide, viral vectors, carbohydrates and antiidiotypic antibodies. In addition, cell based immunotherapy has been adopted in vitro activated lymphocytes and dendritic cells. Most experience has been acquired in ovarian cancer and cervical cancer. Little has been investigated in endometrial and rare gynecologic neoplasms.
The clinical experiences and results achieved with immunotherapy in this setting of patients have been reviewed and the future avenues that are currently being explored have also been discussed.
Export Options
About this article
Cite this article as:
Bellati F., Napoletano C., Ruscito I., Visconti V., Antonilli M., Gasparri M.L., Zizzari I.G., Rahimi H., Palaia I., Rughetti A., Benedetti Panici P. and Nuti M., Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040014
DOI https://dx.doi.org/10.2174/1566524011313040014 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Segmentation and Classification of Lung Cancer: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science A Review on Colorimetric Sensing of Tumor Markers Based on Enzyme-Mimicking Nanomaterials
Current Medicinal Chemistry Synergistic Cytotoxicity Effect of 5-Fluorouracil and SHP2 Inhibitor Demethylincisterol A3 on Cervical Cancer Cell
Anti-Cancer Agents in Medicinal Chemistry Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Cancer and Treatment Modalities
Current Cancer Therapy Reviews Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Glucocorticoid Receptor Functions in HeLa Cells Are Perturbed by 2,3,8,9-tetrachlorodibenzo-p-dioxin (TCDD)
Drug Metabolism Letters Prognostic and Predictive Value of Epithelial to Mesenchymal Transitionassociated Markers in Oral Squamous Cell Carcinoma
Current Proteomics Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Putative Mechanisms of Viral Transmission and Molecular Dysregulation of Mammary Epithelial Cells by Human Papillomavirus: Implications for Breast Cancer
Current Molecular Medicine Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics Induced Fit Docking and Automated QSAR Studies Reveal the ER-α Inhibitory Activity of <i>Cannabis sativa</i> in Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Current Pharmaceutical Design Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets